CA
NBIX icon

CoreCap Advisors’s Neurocrine Biosciences NBIX Stock Holding History

CoreCap Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8K Buy
64
+48
+300% +$7.12K ﹤0.01% 2039
2026
Q1 		$2.11K Hold
16
– – ﹤0.01% 2402
2025
Q4 		$2.27K Buy
+16
New +$2.32K ﹤0.01% 2447
2024
Q3 		– Sell
-1,022
Closed -$141K – 2704
2024
Q2 		$141K Buy
+1,022
New +$140K 0.01% 431
2022
Q4 		$132K Buy
+1,101
New +$129K 0.01% 636

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CoreCap Advisors's NBIX Position: Q2 2026 in Review

CoreCap Advisors increased its Neurocrine Biosciences (NBIX) stake by 300% in Q2 2026, buying an estimated $7.12K and bringing the position to 64 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2039.

CoreCap Advisors first reported a position in NBIX in Q4 2022 and has held it in 5 quarters since. The position peaked at $141K in Q2 2024. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • CoreCap Advisors held 64 shares of Neurocrine Biosciences worth $10.8K as of Q2 2026.
  • CoreCap Advisors bought 48 Neurocrine Biosciences shares in Q2 2026, an estimated $7.12K.
  • Neurocrine Biosciences made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2039 holding.
  • CoreCap Advisors first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 5 quarters since.
  • CoreCap Advisors's Neurocrine Biosciences position peaked at $141K in Q2 2024.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.